BioDrone Therapeutic Inc., a property of MDimune, was established in Seattle, WA, in 2019. The company seeks to facilitate global business collaborations for the BioDrone™ platform technology. Based on its immense therapeutic potential, the company strives to expedite the commercialization of BioDrone™ technology through partnerships with global pharmaceutical companies to extend its therapeutic application and through the integration of advanced technologies from a diverse range of therapeutic areas into the platform.
MDimune Inc., founded in 2015, is a biotech company headquartered in Seoul, Korea, and has been dedicated to the development of the innovative therapeutic platform BioDrone™. The novel BioDrone™ platform technology uses cell-derived vesicles to overcome the limitations of existing cell therapies or achieve target-specific drug delivery. BioDrone™ platform technology is patented in the US, Europe, China, Japan, and Korea. MDimune is actively pursuing business partnerships with biotech and pharmaceutical companies for the potential application of the BioDrone™ technology for various unmet medical needs.